Intelligent Bio Solutions (NASDAQ:INBS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Intelligent Bio Solutions (NASDAQ:INBS) from a sell rating to a hold rating in a research report released on Saturday morning.

Intelligent Bio Solutions Price Performance

NASDAQ:INBS opened at $1.72 on Friday. The firm has a market capitalization of $15.45 million, a P/E ratio of -0.84 and a beta of 4.59. Intelligent Bio Solutions has a 1-year low of $1.10 and a 1-year high of $2.75. The company’s fifty day moving average price is $1.66 and its 200-day moving average price is $1.61.

Intelligent Bio Solutions (NASDAQ:INBS) last released its quarterly earnings data on Friday, August 15th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.25). The business had revenue of $0.84 million during the quarter, compared to analyst estimates of $4.30 million. Intelligent Bio Solutions had a negative return on equity of 231.13% and a negative net margin of 346.22%. Equities analysts anticipate that Intelligent Bio Solutions will post -1.25 EPS for the current fiscal year.

Institutional Trading of Intelligent Bio Solutions

A hedge fund recently bought a new stake in Intelligent Bio Solutions stock. Alyeska Investment Group L.P. acquired a new position in Intelligent Bio Solutions Inc. (NASDAQ:INBS) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 613,892 shares of the company’s stock, valued at approximately $884,000. Alyeska Investment Group L.P. owned 8.88% of Intelligent Bio Solutions at the end of the most recent reporting period. 32.97% of the stock is currently owned by institutional investors.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.